HUT70981A - Conjugate vaccine against group b streptococcus - Google Patents

Conjugate vaccine against group b streptococcus

Info

Publication number
HUT70981A
HUT70981A HU9501260A HU9501260A HUT70981A HU T70981 A HUT70981 A HU T70981A HU 9501260 A HU9501260 A HU 9501260A HU 9501260 A HU9501260 A HU 9501260A HU T70981 A HUT70981 A HU T70981A
Authority
HU
Hungary
Prior art keywords
streptococcus
vaccine against
conjugate vaccine
against group
group
Prior art date
Application number
HU9501260A
Other languages
Hungarian (hu)
Other versions
HU220198B (en
Inventor
Frederick M Ausubel
James L Michel
Dennis L Kasper
Lawrence C Madoff
Original Assignee
Brigham & Womens Hospital
Gen Hospital Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Brigham & Womens Hospital, Gen Hospital Corp filed Critical Brigham & Womens Hospital
Publication of HUT70981A publication Critical patent/HUT70981A/en
Publication of HU220198B publication Critical patent/HU220198B/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/315Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • A61K39/09Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70Vectors or expression systems specially adapted for E. coli
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/60Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031Proteins
    • A61K2039/6068Other bacterial proteins, e.g. OMP
HU9501260A 1992-11-02 1993-11-02 Conjugate vaccine against group b streptococcus HU220198B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US96886692A 1992-11-02 1992-11-02
PCT/US1993/010506 WO1994010317A2 (en) 1992-11-02 1993-11-02 Conjugate vaccine against group b streptococcus

Publications (2)

Publication Number Publication Date
HUT70981A true HUT70981A (en) 1995-11-28
HU220198B HU220198B (en) 2001-11-28

Family

ID=25514876

Family Applications (1)

Application Number Title Priority Date Filing Date
HU9501260A HU220198B (en) 1992-11-02 1993-11-02 Conjugate vaccine against group b streptococcus

Country Status (14)

Country Link
EP (1) EP0669985A1 (en)
JP (1) JPH08505282A (en)
KR (1) KR100349331B1 (en)
AU (1) AU689452B2 (en)
CA (1) CA2146926A1 (en)
FI (1) FI951979A (en)
HU (1) HU220198B (en)
IL (1) IL107458A0 (en)
NO (1) NO951629L (en)
NZ (1) NZ258684A (en)
PL (1) PL177302B1 (en)
RU (1) RU2209247C2 (en)
WO (1) WO1994010317A2 (en)
ZA (1) ZA938171B (en)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6015889A (en) * 1993-03-19 2000-01-18 Gunnar Lindahl Protein rib, a cell surface protein that confers immunity to many strains of the group B streptococcus: process for purification of the protein, reagent kit and pharmaceutical composition
US6284884B1 (en) 1995-06-07 2001-09-04 North American Vaccine, Inc. Antigenic group B streptococcus type II and type III polysaccharide fragments having a 2,5-anhydro-D-mannose terminal structure and conjugate vaccine thereof
US6426074B1 (en) 1997-03-19 2002-07-30 The Brigham And Women's Hospital Inc. Group B Streptococcus vaccine
WO2000006736A2 (en) * 1998-07-27 2000-02-10 Microbial Technics Limited Nucleic acids and proteins from group b streptococcus
US7098182B2 (en) 1998-07-27 2006-08-29 Microbial Technics Limited Nucleic acids and proteins from group B streptococcus
US6890539B2 (en) 1998-12-22 2005-05-10 Microscience, Ltd. Genes and proteins, and their use
OA12425A (en) * 1998-12-22 2006-04-18 Microscience Ltd Outer surface proteins, their genes, and their use.
GB9910375D0 (en) 1999-05-05 1999-06-30 Lindahl Gunnar Vaccine composition
CA2424433A1 (en) * 2000-10-13 2002-04-18 Shire Biochem Inc. Bvh-a2 and bvh-a3 antigens of group b streptococcus
AU2004220590B2 (en) 2003-03-07 2010-02-18 Inhibitex, Inc. Polysaccharide - Staphylococcal surface adhesin carrier protein conjugates for immunization against nosocomial infections
PL2144924T3 (en) 2007-04-16 2017-06-30 Minervax Aps Fusion protein vaccine
CA2734340C (en) 2008-08-28 2019-03-05 Novartis Ag Cell surface display of polypeptide isoforms by stop codon readthrough
CA3001433A1 (en) 2015-10-21 2017-04-27 Minervax Aps Immunogenic fusion protein
CA3004631A1 (en) 2015-12-30 2017-07-06 Minervax Aps Immunogenic complex for eliciting protective immunity against group b streptococcus
EP3638301A1 (en) 2017-06-16 2020-04-22 GlaxoSmithKline Biologicals S.A. Method of treatment
EP4061412A1 (en) 2019-11-22 2022-09-28 GlaxoSmithKline Biologicals S.A. Dosage and administration of a bacterial saccharide glycoconjugate vaccine
EP4066854A1 (en) 2021-03-29 2022-10-05 MinervaX Immunogenic fusion protein

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2754000B2 (en) * 1986-04-16 1998-05-20 ザ ブリガム アンド ウィメンズ ホスピタル,インコーポレイテッド Bacterial antigen, antibody, vaccine and method for producing the same
IL95578A (en) * 1989-09-15 1998-08-16 Gen Hospital Corp Conjugate vaccine formed from a polysaccharide and a c protein of b-streptococcus

Also Published As

Publication number Publication date
CA2146926A1 (en) 1994-05-11
KR950704492A (en) 1995-11-20
NO951629L (en) 1995-07-03
NO951629D0 (en) 1995-04-28
WO1994010317A3 (en) 1994-07-07
EP0669985A1 (en) 1995-09-06
FI951979A0 (en) 1995-04-26
WO1994010317A2 (en) 1994-05-11
ZA938171B (en) 1995-03-07
RU2209247C2 (en) 2003-07-27
HU220198B (en) 2001-11-28
PL308555A1 (en) 1995-08-21
PL177302B1 (en) 1999-10-29
AU689452B2 (en) 1998-04-02
NZ258684A (en) 1997-04-24
KR100349331B1 (en) 2003-01-06
IL107458A0 (en) 1994-02-27
AU5665494A (en) 1994-05-24
FI951979A (en) 1995-06-29
JPH08505282A (en) 1996-06-11

Similar Documents

Publication Publication Date Title
CZ197595A3 (en) Vaccine preparations
EP0566368A3 (en) Cosmetic conjugate
AP9300541A0 (en) Vaccines
AP9300530A0 (en) Vaccines
IL107458A0 (en) Conjugate vaccine against group b streptococcus
ZA937034B (en) Group B streptococcus type II and type V polysaccharide-protein conjugate vaccines
EP0468714A3 (en) Peptide-polysaccharide-protein conjugate vaccines
GB9215233D0 (en) Vaccines
AU4970193A (en) IPNV vaccine
GB9213559D0 (en) Vaccines
GB9214871D0 (en) Vaccines
GB9201023D0 (en) Vaccines
AU5626998A (en) Conjugate vaccine against group B Streptococcus
IL115197A0 (en) Vaccine preparations
GB9202933D0 (en) Vaccines
GB9226768D0 (en) Vaccines
SG48106A1 (en) Pneumococcal polyaccharide conjugate vaccine
ZA933541B (en) Vaccines
GB9108748D0 (en) Conjugate
GB9206786D0 (en) Vaccine
GB9307028D0 (en) Vaccine
GB9206788D0 (en) Vaccine
GB9206789D0 (en) Vaccine
GB9206797D0 (en) Vaccine
GB9213308D0 (en) Vaccine

Legal Events

Date Code Title Description
HMM4 Cancellation of final prot. due to non-payment of fee